Urine markers for detection and surveillance of bladder cancer

Evanguelos Xylinas, Luis A. Kluth, Malte Rieken, Pierre I. Karakiewicz, Yair Lotan, Shahrokh F. Shariat

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Objectives: Bladder cancer detection and surveillance includes cystoscopy and cytology. Urinary cytology is limited by its low sensitivity for low-grade tumors. Urine markers have been extensively studied to help improve the diagnosis of bladder cancer with the goal of complementing or even replacing cystoscopy. However, to date, no marker has reached widespread use owing to insufficient evidence for clinical benefit. Material and methods: Pubmed/Medline search was conducted to identify original articles, review articles, and editorials regarding urine-based biomarkers for screening, early detection, and surveillance of urothelial carcinoma of the bladder. Searches were limited to the English language, with a time frame of 2000 to 2013. Keywords included urothelial carcinoma, bladder cancer, transitional cell carcinoma, biomarker, marker, urine, diagnosis, recurrence, and progression. Results: Although several urinary markers have shown higher sensitivity compared with cytology, it remains insufficient to replace cystoscopy. Moreover, most markers suffer from lower specificity than cytology. In this review, we aimed to summarize the current knowledge on commercially available and promising investigational urine markers for the detection and surveillance of bladder cancer. Conclusions: Well-designed protocols and prospective, controlled trials are needed to provide the basis to determine whether integration of biomarkers into clinical decision making will be of value for bladder cancer detection and screening in the future.

Original languageEnglish (US)
Pages (from-to)222-229
Number of pages8
JournalUrologic Oncology: Seminars and Original Investigations
Volume32
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Urinary Bladder Neoplasms
Cystoscopy
Urine
Cell Biology
Biomarkers
Carcinoma
Transitional Cell Carcinoma
Early Detection of Cancer
PubMed
Urinary Bladder
Language
Recurrence
Neoplasms

Keywords

  • Biomarker
  • Bladder cancer
  • Detection
  • Molecular marker
  • Surveillance
  • Urine
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Medicine(all)

Cite this

Urine markers for detection and surveillance of bladder cancer. / Xylinas, Evanguelos; Kluth, Luis A.; Rieken, Malte; Karakiewicz, Pierre I.; Lotan, Yair; Shariat, Shahrokh F.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 32, No. 3, 2014, p. 222-229.

Research output: Contribution to journalArticle

Xylinas, Evanguelos ; Kluth, Luis A. ; Rieken, Malte ; Karakiewicz, Pierre I. ; Lotan, Yair ; Shariat, Shahrokh F. / Urine markers for detection and surveillance of bladder cancer. In: Urologic Oncology: Seminars and Original Investigations. 2014 ; Vol. 32, No. 3. pp. 222-229.
@article{c68eafe7d0b645b08e07bc6129245eb1,
title = "Urine markers for detection and surveillance of bladder cancer",
abstract = "Objectives: Bladder cancer detection and surveillance includes cystoscopy and cytology. Urinary cytology is limited by its low sensitivity for low-grade tumors. Urine markers have been extensively studied to help improve the diagnosis of bladder cancer with the goal of complementing or even replacing cystoscopy. However, to date, no marker has reached widespread use owing to insufficient evidence for clinical benefit. Material and methods: Pubmed/Medline search was conducted to identify original articles, review articles, and editorials regarding urine-based biomarkers for screening, early detection, and surveillance of urothelial carcinoma of the bladder. Searches were limited to the English language, with a time frame of 2000 to 2013. Keywords included urothelial carcinoma, bladder cancer, transitional cell carcinoma, biomarker, marker, urine, diagnosis, recurrence, and progression. Results: Although several urinary markers have shown higher sensitivity compared with cytology, it remains insufficient to replace cystoscopy. Moreover, most markers suffer from lower specificity than cytology. In this review, we aimed to summarize the current knowledge on commercially available and promising investigational urine markers for the detection and surveillance of bladder cancer. Conclusions: Well-designed protocols and prospective, controlled trials are needed to provide the basis to determine whether integration of biomarkers into clinical decision making will be of value for bladder cancer detection and screening in the future.",
keywords = "Biomarker, Bladder cancer, Detection, Molecular marker, Surveillance, Urine, Urothelial carcinoma",
author = "Evanguelos Xylinas and Kluth, {Luis A.} and Malte Rieken and Karakiewicz, {Pierre I.} and Yair Lotan and Shariat, {Shahrokh F.}",
year = "2014",
doi = "10.1016/j.urolonc.2013.06.001",
language = "English (US)",
volume = "32",
pages = "222--229",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Urine markers for detection and surveillance of bladder cancer

AU - Xylinas, Evanguelos

AU - Kluth, Luis A.

AU - Rieken, Malte

AU - Karakiewicz, Pierre I.

AU - Lotan, Yair

AU - Shariat, Shahrokh F.

PY - 2014

Y1 - 2014

N2 - Objectives: Bladder cancer detection and surveillance includes cystoscopy and cytology. Urinary cytology is limited by its low sensitivity for low-grade tumors. Urine markers have been extensively studied to help improve the diagnosis of bladder cancer with the goal of complementing or even replacing cystoscopy. However, to date, no marker has reached widespread use owing to insufficient evidence for clinical benefit. Material and methods: Pubmed/Medline search was conducted to identify original articles, review articles, and editorials regarding urine-based biomarkers for screening, early detection, and surveillance of urothelial carcinoma of the bladder. Searches were limited to the English language, with a time frame of 2000 to 2013. Keywords included urothelial carcinoma, bladder cancer, transitional cell carcinoma, biomarker, marker, urine, diagnosis, recurrence, and progression. Results: Although several urinary markers have shown higher sensitivity compared with cytology, it remains insufficient to replace cystoscopy. Moreover, most markers suffer from lower specificity than cytology. In this review, we aimed to summarize the current knowledge on commercially available and promising investigational urine markers for the detection and surveillance of bladder cancer. Conclusions: Well-designed protocols and prospective, controlled trials are needed to provide the basis to determine whether integration of biomarkers into clinical decision making will be of value for bladder cancer detection and screening in the future.

AB - Objectives: Bladder cancer detection and surveillance includes cystoscopy and cytology. Urinary cytology is limited by its low sensitivity for low-grade tumors. Urine markers have been extensively studied to help improve the diagnosis of bladder cancer with the goal of complementing or even replacing cystoscopy. However, to date, no marker has reached widespread use owing to insufficient evidence for clinical benefit. Material and methods: Pubmed/Medline search was conducted to identify original articles, review articles, and editorials regarding urine-based biomarkers for screening, early detection, and surveillance of urothelial carcinoma of the bladder. Searches were limited to the English language, with a time frame of 2000 to 2013. Keywords included urothelial carcinoma, bladder cancer, transitional cell carcinoma, biomarker, marker, urine, diagnosis, recurrence, and progression. Results: Although several urinary markers have shown higher sensitivity compared with cytology, it remains insufficient to replace cystoscopy. Moreover, most markers suffer from lower specificity than cytology. In this review, we aimed to summarize the current knowledge on commercially available and promising investigational urine markers for the detection and surveillance of bladder cancer. Conclusions: Well-designed protocols and prospective, controlled trials are needed to provide the basis to determine whether integration of biomarkers into clinical decision making will be of value for bladder cancer detection and screening in the future.

KW - Biomarker

KW - Bladder cancer

KW - Detection

KW - Molecular marker

KW - Surveillance

KW - Urine

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84897064727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897064727&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2013.06.001

DO - 10.1016/j.urolonc.2013.06.001

M3 - Article

C2 - 24054865

AN - SCOPUS:84897064727

VL - 32

SP - 222

EP - 229

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 3

ER -